Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk

被引:16
|
作者
Monte, Simona [1 ]
Macchia, Alejandro [1 ,2 ]
Romero, Marilena [1 ]
D'Ettorre, Antonio [1 ]
Giuliani, Rachele [1 ]
Tognoni, Gianni [1 ]
机构
[1] Consorzio Mario Negri Sud, Lab Pharmacoepidemiol, Dept Clin Pharmacol & Epidemiol, Chieti, Italy
[2] GESICA Fdn, Buenos Aires, DF, Argentina
关键词
Cardiovascular risk; Depression; Epidemiology; CORONARY-HEART-DISEASE; NUTRITION EXAMINATION SURVEY; MYOCARDIAL-INFARCTION; DEPRESSIVE SYMPTOMS; BLOOD-PRESSURE; YOUNG-ADULTS; FOLLOW-UP; ATRIAL-FIBRILLATION; METABOLIC SYNDROME; ELDERLY-PATIENTS;
D O I
10.1007/s00228-009-0692-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To identify a cohort of subjects without treatment for any cardiovascular risk and analyze the potential causative role of treatment for depression on the development of major cardiovascular outcomes during 2 years of follow-up. We carried out a record-linkage analysis of hospital discharge records, prescription databases and vital statistics for all consecutive patients aged 30 years or older in one Italian region during a 4-year period. Depression was defined in terms of exposure to at least three prescriptions of antidepressant drugs within 1 year. Patients had no history of treatment with cardiovascular or antidiabetic agents and had not been hospitalized with a diagnosis of any cardiovascular condition in the preceding year. Follow-up was extended up to 2 years or to time to occurrence of major outcomes defined as either all-cause mortality, hospitalization for any cardiovascular cause or chronic exposure to cardiovascular drugs (antihypertensive, statins, antidiabetics). The results are expressed hazard ratios (HRs) and 95% confidence intervals (CIs) within age categories (30-49, 50-59, a parts per thousand yen60 years). A total of 105,573 persons without treated cardiovascular risk at baseline were identified, among whom 1,129 (1.1%) had been chronically exposed to antidepressant treatment. Treated depression determined an increased risk of all cause-mortality (HR 1.88, 95% CI 1.33-2.66, p < 0.001) and of subsequent treatment with antidiabetic agents (HR 0.89, 95% CI 1.34-2.66, p < 0.001), statins (HR 1.87, 95% CI 1.53-2.29, p < 0.001) and antihypertensive drugs (HR 1.25, 95% CI 1.07-1.47, p = 0.006). Among the general population without treated cardiovascular risk, pharmacologic treatment for depression was associated with an increase in all-cause mortality and major cardiovascular outcomes.
引用
收藏
页码:1131 / 1138
页数:8
相关论文
共 50 条
  • [31] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    Lincoff, A. Michael
    Brown-Frandsen, Kirstine
    Colhoun, Helen M.
    Deanfield, John
    Emerson, Scott S.
    Esbjerg, Sille
    Hardt-Lindberg, Soren
    Hovingh, G. Kees
    Kahn, Steven E.
    Kushner, Robert F.
    Lingvay, Ildiko
    Oral, Tugce K.
    Michelsen, Marie M.
    Plutzky, Jorge
    Tornoe, Christoffer W.
    Ryan, Donna H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (24) : 2221 - 2232
  • [32] Effects of Cardiovascular Risk Factor Variability on Health Outcomes
    Lee, Seung-Hwan
    Kim, Mee Kyoung
    Rhee, Eun-Jung
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 217 - 226
  • [33] Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies
    Biffi, A.
    Scotti, L.
    Corrao, G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (04) : 487 - 497
  • [34] Ideal Cardiovascular Health in Childhood and Cardiometabolic Outcomes in Adulthood The Cardiovascular Risk in Young Finns Study
    Laitinen, Tomi T.
    Pahkala, Katja
    Magnussen, Costan G.
    Viikari, Jorma S. A.
    Oikonen, Mervi
    Taittonen, Leena
    Mikkila, Vera
    Jokinen, Eero
    Hutri-Kahonen, Nina
    Laitinen, Tomi
    Kahonen, Mika
    Lehtimaki, Terho
    Raitakari, Olli T.
    Juonala, Markus
    CIRCULATION, 2012, 125 (16) : 1971 - 1978
  • [35] Micronutrients to control cardiovascular risk
    Bonnefont-Rousselot, Dominique
    NUTRITION CLINIQUE ET METABOLISME, 2012, 26 (01): : 14 - 21
  • [36] Diabetes, Cardiovascular Risk and Nephropathy
    Hahr, Allison J.
    Molitch, Mark E.
    CARDIOLOGY CLINICS, 2010, 28 (03) : 467 - +
  • [37] HIV and General Cardiovascular Risk
    Capili, Bernadette
    Anastasi, Joyce K.
    Ogedegbe, Olugbenga
    JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2011, 22 (05): : 362 - 375
  • [38] Sleep apnea and cardiovascular risk
    Rajachandran, Manu
    Nickel, Nils
    Lange, Richard A.
    CURRENT OPINION IN CARDIOLOGY, 2023, 38 (05) : 456 - 461
  • [39] Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease
    Wong, Nathan D.
    Zhao, Yanglu
    Xiang, Pin
    Coll, Blai
    Lopez, J. Antonio G.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 137 : 7 - 11
  • [40] Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease
    Aronow, Wilbert S.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 1822 - 1825